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ABSTRACT
Dengue, a mosquito-borne viral disease is a serious public health concern in many 
countries around the world. In Malaysia, suspected cases of dengue infection increase 
dramatically every year. Dengue infections cause a variable spectrum of 
manifestations ranging from dengue fever (DF) to dengue haemorrhagic fever (DHF) 
with plasma leakage that may lead to hypovolaemic shock, called dengue shock 
syndrome (DSS). Recent studies suggested the potential role of Fc gamma receptors 
(FCGRs) in the pathogenesis of dengue. The aim of this study was to determine the 
frequencies o f copy number variation (CNV) of the FCGR1A gene and correlate the 
FCGR1A profile with its gene expression and serum protein level in dengue patients 
with vascular leakage and those without vascular leakage. Extracted DNA, RNA and 
serum were isolated from blood and use to quantify FCGR1A CNV, gene expression 
and protein concentration using quantitative real-time polymerase chain reaction 
(qPCR), reverse transcription-qPCR (RT-qPCR) and enzyme-linked immunosorbent 
assay (ELISA) respectively. One hundred dengue patients with signs of vascular 
leakage (case) and without vascular leakage (control), and 50 healthy subjects 
(normal) tested. Statistical analysis revealed that CNV of FCGR1A was significantly 
associated with dengue when compared to the normal controls. The circulating 
FcyRlA were also found to be significantly different between dengue patients and 
normal controls. However, there was no difference between dengue patients and 
normal controls, and dengue patients with vascular leakage and those without vascular 
leakage. These findings suggested that the FcyRlA plays a role in the susceptibility of 
dengue infection, however, showed no evidence in contributing to the severity of 
dengue. Although the correlation between these three experiments were not 
significantly related, the role of FCGR1A in vascular leakage should not be excluded. 
Further studies with larger sample size is needed to confirm this finding.
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CHAPTER ONE 
INTRODUCTION
1.1 BACKGROUND OF STUDY
Dengue is one of the most important mosquito borne diseases and has become 
a major public health concern throughout the world (WHO, 2009). It is found largely 
in the areas o f tropics and subtropics climate, and hot moist year (Ferreira, 2012). 
Dengue appears as endemic in Malaysia and many countries in the tropical and 
subtropical regions, predominantly in urban and semi-urban areas (WHO, 2009). This 
is mainly attributed to the uncontrolled dengue prevention and management, which 
consequently provides a suitable breeding habitat for the mosquitos (WHO 2009). The 
total of dengue cases has dramatically increased since the last few decades with 
increasing number of deaths. Globally, more than one-third of the world’s population 
is living in areas at risk for transmission and infection of dengue fever (WHO, 2013).
The causative agent of dengue is dengue virus (DENV) containing a positive 
single-stranded RNA of approximately 11 kb in size (Stollar et al., 1967). DENV 
comprises o f four serotypes namely, DENV1-DENV4. Dengue virus belongs to a 
flavivirus family that is transmitted by the bite of an infected female mosquito Aedes 
sp. (in particular Aedes aegypti), as a vector for transmitting and spreading of the 
dengue fever. The mosquito usually bites at dusk and dawn even during the day. They 
prefer breeding areas at stagnant clean water such as flower pots, discarded tyres, wet 
shower floor and toilet tanks which allow the mosquito to breed in the residence. 
Currently there is no available vaccine for dengue, therefore effective prevention and 
control is required by reducing the habitat and the number o f mosquitoes, and to limit 
exposure to Aedes aegypti bites.
Dengue infection induces a wide spectrum of clinical manifestations, ranging 
from asymptomatic to undifferentiated fever, dengue fever (DF) to dengue 
haemorrhagic fever (DHF) with plasma leakage that may lead to hypovolaemic shock, 
and dengue shock syndrome (DSS) (WHO, 1997). Despite difficulties in the use of 
DHF classification (Guha-Sapir and Schimmer, 2005; Deen et al., 2006; Rigau-Perez,
2006), WHO had reclassified dengue into levels of severity by using a set of clinical
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